Cysteamine Prodrug Dosing for Stable Plasma Levels and Fewer Side Effects

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Cysteamine's therapeutic potential is hindered by unpleasant sensory properties, gastrointestinal side effects, frequent dosing requirements, and variability in pharmacokinetics, leading to non-compliance and sub-therapeutic levels in patients.

Innovation Solution

A method involving administering specific doses of cysteamine precursors, reducing agents, and pantetheinase inducing agents at defined intervals to stabilize and enhance cysteamine levels, along with formulations for immediate, delayed, or sustained release to minimize side effects and improve efficacy.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If high doses of cysteamine are administered to achieve therapeutic levels, then therapeutic efficacy is improved, but gastrointestinal side effects and body odor increase

Engineering Contradiction:

Improvetherapeutic efficacyVSAvoidgastrointestinal side effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent uses carnitine as an intermediary substance that facilitates cysteamine delivery. Carnitine forms a complex with cysteamine that improves absorption and reduces direct irritation to the gastrointestinal tract, thereby maintaining therapeutic efficacy while reducing side effects

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent changes the chemical parameters by administering cysteamine in the form of esters (e.g., cysteamine bitartrate, cysteamine hydrochloride) rather than free cysteamine. This parameter change modifies the drug's properties to reduce gastrointestinal irritation while maintaining therapeutic effectiveness

Inventive Principle:

Principle #35Parameter changes

2Stability of the object's composition

If frequent dosing is administered to maintain therapeutic levels, then blood concentration stability is improved, but patient compliance deteriorates

Engineering Contradiction:

Improveblood concentration stabilityVSAvoidpatient compliance

Core Design Contradiction:

Stability of the object's compositionVSEase of operation

Solution Approach 1:

The patent achieves continuous therapeutic action through sustained-release formulations that gradually release cysteamine over extended periods. This continuous delivery maintains stable blood concentrations without requiring frequent dosing, thereby improving patient compliance

Inventive Principle:

Principle #20Continuity of useful action

Solution Approach 2:

The patent employs dynamic dosing regimens where the dosing interval and amount are adjusted based on individual patient response and pharmacokinetic parameters. This dynamic approach optimizes blood concentration stability while minimizing the dosing frequency burden on patients

Inventive Principle:

Principle #15Dynamics

3Speed

If immediate release formulations are used, then rapid therapeutic effect is achieved, but peak concentrations and side effects increase

Engineering Contradiction:

Improveonset of actionVSAvoidpeak concentration side effects

Core Design Contradiction:

SpeedVSObject-generated harmful factors

Solution Approach 1:

The patent employs periodic dosing with sustained-release formulations that provide controlled, periodic release of cysteamine. This periodic action maintains therapeutic levels while avoiding dangerous peak concentrations, reducing side effects associated with high peak levels

Inventive Principle:

Principle #19Periodic action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Stabilizes cysteamine levels, reduces peak concentrations, and enhances therapeutic efficacy while minimizing side effects, allowing for improved compliance and treatment of cysteamine-sensitive disorders.

Implementation Method 1

The thiol group of cysteamine can reduce free radicals and other oxidized compounds that may be detrimental to cells, thereby contributing to redox homeostasis

Methodology Applied

Scientific EffectRedox reactions: Redox Reactions

Implementation Method 2

Cysteamine can also form disulfides with cysteine residues of proteins, thereby affecting protein structure and function

Methodology Applied

Scientific EffectThiol-disulfide exchange: Chemical Bonding

Implementation Method 3

Cysteamine is a chelating agent, with particular affinity for copper

Methodology Applied

Scientific EffectChelation: Absorption (physical)

Data Source

PatentUS12569456B2Methods for the treatment of cysteamine sensitive disorders

Publication Date: 2026.03.10 THIOGENESIS THERAPEUTICS INC

AI summary

The invention features methods for the treatment of cystinosis and other cysteamine sensitive disorders in a subject including administration of a disulfide convertible to cysteamine in vivo. The methods can include the separate administration of a reducing agent to the subject to increase the bioavailability and extend the plasma pharmacokinetic profile of the cysteamine produced following administration of the disulfide. The methods permit sustained cysteamine plasma concentrations in a subject.